Maze Therapeutics CSBO Sells 7,500 Shares Following Strong Trial Results and Q4 Financials
Atul Dandekar, Chief Strategy and Business Officer of Maze Therapeutics, sold 7,500 shares of common stock for approximately $190,000 on April 29, 2026. The transaction, based on a weighted average price of $25.37, reduced his direct ownership stake and reflects a derivative-driven option exercise and immediate sale. The move follows recent strong trial results and Q4 financials for the company.
Tickers: $MAZE